Please login to the form below

Not currently logged in
Email:
Password:

Bayer shares rise on Novartis takeover rumour

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

On 15 August 2007, rumours that Novartis might offer EUR 70 per share saw Bayer's stock rise by up to seven per cent.

Bayer has neither confirmed nor denied the takeover, while Novartis has also remained silent on the matter.

Bayer shares rose 3.2 per cent to rest at EUR 56.41 in morning trading on 22 August, while Novartis' shares were slightly lower.

Dresdner Kleinwort analysts have been skeptical that Novartis, which has a market capitalisation of USD 143bn, would make a play for Bayer, which is valued at USD 54bn at the current share price.

Another reason to disbelieve the rumour is that Bayer recently expanded its healthcare business with the 2006 EUR 17bn acquisition of Schering.

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics